Total Valuation
Imugene has a market cap or net worth of $18.40M. The enterprise value is $43.81.
Market Cap$18.40M
Enterprise Value$43.81
Share Statistics
Imugene has 548,901,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding548,901,500
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Imugene’s return on equity (ROE) is -11.69 and return on invested capital (ROIC) is -480.51%.
Return on Equity (ROE)-11.69
Return on Assets (ROA)-4.57
Return on Invested Capital (ROIC)-480.51%
Return on Capital Employed (ROCE)-8.32
Revenue Per Employee0.00
Profits Per Employee-7.52M
Employee Count14
Asset Turnover0.00
Inventory Turnover1.55
Valuation Ratios
The current PE Ratio of Imugene is ―. Imugene’s PEG ratio is 0.00.
PE Ratio―
PS Ratio0.00
PB Ratio4.16
Price to Fair Value4.16
Price to FCF-0.84
Price to Operating Cash Flow-0.37
PEG Ratio0.00
Income Statement
In the last 12 months, Imugene had revenue of 0.00 and earned -105.34M in profits. Earnings per share was -0.32.
Revenue0.00
Gross Profit-6.84M
Operating Income-74.95M
Pretax Income-107.34M
Net Income-105.34M
EBITDA-68.11M
Earnings Per Share (EPS)-0.32
Cash Flow
In the last 12 months, operating cash flow was -44.85M and capital expenditures -3.00, giving a free cash flow of -44.85M billion.
Operating Cash Flow-44.85M
Free Cash Flow-44.85M
Free Cash Flow per Share-0.08
Dividends & Yields
Imugene pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.07
52-Week Price Change-79.55%
50-Day Moving Average0.07
200-Day Moving Average0.13
Relative Strength Index (RSI)39.79
Average Volume (3m)24.22K
Important Dates
Imugene upcoming earnings date is Mar 3, 2027, TBA (Confirmed).
Last Earnings DateSep 2, 2026
Next Earnings DateMar 3, 2027
Ex-Dividend Date―
Financial Position
Imugene as a current ratio of 0.70, with Debt / Equity ratio of 69.91%
Current Ratio0.70
Quick Ratio0.39
Debt to Market Cap0.17
Net Debt to EBITDA-0.05
Interest Coverage Ratio-597.34
Taxes
In the past 12 months, Imugene has paid -2.00M in taxes.
Income Tax-2.00M
Effective Tax Rate0.02
Enterprise Valuation
Imugene EV to EBITDA ratio is -0.60, with an EV/FCF ratio of -0.92.
EV to Sales0.00
EV to EBITDA-0.60
EV to Free Cash Flow-0.92
EV to Operating Cash Flow-0.92
Balance Sheet
Imugene has $2.63M in cash and marketable securities with $6.30M in debt, giving a net cash position of -$3.67M billion.
Cash & Marketable Securities$2.63M
Total Debt$6.30M
Net Cash-$3.67M
Net Cash Per Share>-$0.01
Tangible Book Value Per Share$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Imugene is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-6.92%